Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 381


The role of tumor hypoxia in MUC1-positive breast carcinomas.

Zanetti JS, Soave DF, Oliveira-Costa JP, da Silveira GG, Ramalho LN, Garcia SB, Zucoloto S, Ribeiro-Silva A.

Virchows Arch. 2011 Oct;459(4):367-75. doi: 10.1007/s00428-011-1142-6. Epub 2011 Sep 3.


Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.

Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E.

J Natl Cancer Inst. 2001 Feb 21;93(4):309-14.


Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.

Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E.

Cancer. 2003 Mar 15;97(6):1573-81.


Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.

Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, Iwase H.

Breast Cancer Res Treat. 2008 Aug;110(3):465-75. Epub 2007 Sep 6.


Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.

Wang Z, Shi Q, Wang Z, Gu Y, Shen Y, Sun M, Deng M, Zhang H, Fang J, Zhang S, Xie F.

Pathol Res Pract. 2011 Aug 15;207(8):505-13. doi: 10.1016/j.prp.2011.06.009. Epub 2011 Jul 28.


Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients.

Peurala E, Koivunen P, Bloigu R, Haapasaari KM, Jukkola-Vuorinen A.

Breast Cancer Res Treat. 2012 May;133(1):179-88. doi: 10.1007/s10549-011-1750-5. Epub 2011 Aug 30.


Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer.

Schoppmann SF, Fenzl A, Schindl M, Bachleitner-Hofmann T, Nagy K, Gnant M, Horvat R, Jakesz R, Birner P.

Breast Cancer Res Treat. 2006 Sep;99(2):135-41. Epub 2006 Mar 23.


Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas.

Pansare V, Munkarah AR, Schimp V, Haitham Arabi M, Saed GM, Morris RT, Ali-Fehmi R.

Mod Pathol. 2007 Jan;20(1):35-43. Epub 2006 Nov 10.


The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.

van der Vegt B, de Roos MA, Peterse JL, Patriarca C, Hilkens J, de Bock GH, Wesseling J.

Histopathology. 2007 Sep;51(3):322-35. Epub 2007 Jul 23.


MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression.

Aubert S, Fauquette V, Hémon B, Lepoivre R, Briez N, Bernard D, Van Seuningen I, Leroy X, Perrais M.

Cancer Res. 2009 Jul 15;69(14):5707-15. doi: 10.1158/0008-5472.CAN-08-4905. Epub 2009 Jun 23.


Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival.

Campo L, Turley H, Han C, Pezzella F, Gatter KC, Harris AL, Fox SB.

J Pathol. 2005 Apr;205(5):585-91.


Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas.

Okada K, Osaki M, Araki K, Ishiguro K, Ito H, Ohgi S.

Anticancer Res. 2005 Jul-Aug;25(4):3003-9.


[HIF-1alpha expression and relationship involving tumor cell proliferation and angiogenesis in human breast carcinoma].

Hao LS, Wang G, Qian K, Luo T, Li XJ, Wu XT.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jan;38(1):60-3. Chinese.


Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.

Hein S, Müller V, Köhler N, Wikman H, Krenkel S, Streichert T, Schweizer M, Riethdorf S, Assmann V, Ihnen M, Beck K, Issa R, Jänicke F, Pantel K, Milde-Langosch K.

Breast Cancer Res Treat. 2011 Sep;129(2):347-60. doi: 10.1007/s10549-010-1219-y. Epub 2010 Oct 23.


Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.

Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G; Austrian Breast and Colorectal Cancer Study Group..

Clin Cancer Res. 2002 Jun;8(6):1831-7.


Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.

Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

Clin Cancer Res. 2007 Dec 15;13(24):7388-93.


Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast.

Kuijper A, van der Groep P, van der Wall E, van Diest PJ.

Breast Cancer Res. 2005;7(5):R808-18. Epub 2005 Aug 5.


Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer.

Kwon HC, Kim SH, Oh SY, Lee S, Kwon KA, Lee JH, Choi HJ, Park KJ, Lee HS, Roh MS, Kim HJ.

Cancer Sci. 2010 Jun;101(6):1557-61. doi: 10.1111/j.1349-7006.2010.01553.x. Epub 2010 Mar 4.


Immunohistochemical investigation of the angiogenic proteins VEGF, HIF-1α and CD34 in invasive ductal carcinoma of the breast.

Maschio LB, Madallozo BB, Capellasso BA, Jardim BV, Moschetta MG, Jampietro J, Soares FA, Zuccari DA.

Acta Histochem. 2014 Jan;116(1):148-57. doi: 10.1016/j.acthis.2013.06.005. Epub 2013 Jul 27.


Supplemental Content

Support Center